Search results

  1. Upper aerodigestive tract cancer

    Everything NICE has said on assessing and managing upper aerodigestive tract cancer in young people and adults in an interactive flowchart

  2. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  3. Skin cancer

    Everything NICE has said on skin cancers, including melanoma, basal cell carcinoma and squamous cell carcinoma in an interactive flowchart

  4. Neutropenic sepsis

    Everything NICE has said on preventing, identifying and managing neutropenic sepsis in children, young people and adults in an interactive flowchart

  5. Hypertension in pregnancy

    Everything NICE has said on diagnosing and managing hypertension in pregnancy in an interactive flowchart

  6. Preventing type 2 diabetes

    Everything NICE has said on preventing type 2 diabetes in an interactive flowchart

  7. Sunlight exposure: risks and benefits

    Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

  8. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  9. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  10. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  11. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  12. Pneumonia

    Everything NICE has said on assessing and managing community- and hospital-acquired pneumonia in an interactive flowchart

  13. Acute upper gastrointestinal bleeding

    Everything NICE has said on risk assessment and management of acute upper gastrointestinal bleeding in people 16 years and older in an interactive flowchart

  14. Transition from children's to adults' services

    Everything NICE has said on the transition from children's to adults' services for young people in health or social care in an interactive flowchart

  15. Multimorbidity

    Everything NICE has said on optimising care for people with 2 or more long-term health conditions in an interactive flowchart

  16. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    The purpose of this guideline is to help healthcare professionals prevent, detect and manage acute kidney injury in adults in hospital with known or suspected COVID-19. This is important to improve outcomes and reduce the need for renal replacement therapy.

  17. Food allergy in under 19s

    Everything NICE has said on diagnosing and assessing food allergy in children and young people in primary care and community settings in an interactive flowchart

  18. Managing medicines in care homes

    Everything NICE has said on systems and processes for managing medicines in care homes in an interactive flowchart

  19. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)

    The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID-19 pandemic. This includes people presenting to hospital with moderate to severe community-acquired pneumonia and people who develop pneumonia while in hospital. It will enable services to make the best use of NHS resources.

  20. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  21. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.

  22. COVID-19 rapid guideline: critical care in adults (NG159)

    The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  23. Parkinson's disease

    Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart

  24. Metastatic spinal cord compression

    Everything NICE has said on detecting and managing metastatic spinal cord compression in adults with cancer in an interactive flowchart

  25. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

  26. Spasticity in children and young people

    Everything NICE has said on managing spasticity and co-existing motor disorders in children and young people in an interactive flowchart

  27. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice. For general advice on managing COVID-19 symptoms, see the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community .

  28. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  29. COVID-19 rapid guideline: acute myocardial injury (NG171)

    The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease.

  30. Stroke

    Everything NICE has said on preventing, diagnosing and managing stroke and transient ischaemic attack (TIA) in people over 16 in an interactive flowchart

  31. Musculoskeletal conditions

    Everything NICE has said on musculoskeletal conditions in an interactive flowchart

  32. Pressure ulcers

    Everything NICE has said on preventing and managing pressure ulcers in all age groups in primary care and community settings in an interactive flowchart

  33. Leg ulcers

    Everything NICE has said on leg ulcers in an interactive flowchart

  34. COVID-19 rapid guideline: cystic fibrosis (NG170)

    The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.

  35. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    The purpose of this guideline is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  36. Respiratory conditions

    Everything NICE has said on respiratory conditions in an interactive flowchart

  37. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

  38. Atrial fibrillation

    Everything NICE has said on diagnosing and managing atrial fibrillation in an interactive flowchart

  39. Osteoporosis

    Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

  40. COVID-19 rapid guideline: severe asthma (NG166)

    The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  41. Skin conditions

    Everything NICE has said on managing skin conditions and skin damage in an interactive flowchart

  42. Foot care for people with diabetes

    Everything NICE has said on preventing and managing foot problems in children, young people and adults with type 1 or 2 diabetes in an interactive flowchart

  43. Dementia

    Everything NICE has said on assessment, management and support for people living with dementia and Alzheimer's disease and their carers in an interactive flowchart